Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
K. Yamaguchi
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
ORCID:
0000-0001-6887-5709
Observed ORCID:
0000-0001-6887-5709
OpenAlex ID:
A5121038917
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
2026
·
Y.Y. Janjigian
, K. Shitara
, et al.
·
Annals of Oncology
·
39
PDF
199MO First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study
2025
·
T. Yoshino
, T.W. Kim
, et al.
·
Annals of Oncology
313P Characteristics, treatment patterns, and outcomes with first-line nivolumab plus chemotherapy vs chemotherapy in CheckMate 649 patients by regions
2025
·
L. Shen
, K. Shitara
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
3
Citation count:
39
H-index:
1
I10-index:
1
Year
Topic
Type